List of Excipients in Branded Drug GLEOSTINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc	GLEOSTINE	lomustine	24338-341	MAGNESIUM STEARATE
Azurity Pharmaceuticals Inc	GLEOSTINE	lomustine	24338-341	MANNITOL
NextSource Biotechnology LLC	GLEOSTINE	lomustine	58181-3041	MAGNESIUM STEARATE
NextSource Biotechnology LLC	GLEOSTINE	lomustine	58181-3041	MANNITOL

Gleostine Excipient Strategy and Commercial Opportunities

Last updated: September 17, 2026

Gleostine is an oral lomustine capsule used primarily for relapsed or progressive brain tumors. Its commercial opportunity is driven less by novel active-ingredient exclusivity than by supply reliability, capsule manufacturing, hazardous-drug controls, hospital procurement, and differentiated formulations. The most credible excipient opportunities involve capsule-shell optimization, colorant substitution, stability improvement, packaging, and specialty compounding support rather than a new oral delivery platform.

What is Gleostine and which excipients are used?

Gleostine contains lomustine, an alkylating nitrosourea administered orally on an intermittent dosing schedule. The product is supplied as single-dose capsules in 10 mg, 40 mg, and 100 mg strengths. The FDA prescribing information identifies inactive ingredients that include gelatin, titanium dioxide, and capsule colorants, including FD&C Blue No. 1 and D&C Yellow No. 10, depending on capsule strength and presentation [1].

The capsule is swallowed whole. The formulation does not depend on taste masking, sustained release, enteric protection, or an advanced drug-delivery system. Its principal formulation requirements are:

• Accurate low-dose powder filling.
• Uniform content across three strengths.
• Capsule-shell integrity during storage and handling.
• Protection from moisture and light.
• Compatibility with cytotoxic-drug containment procedures.
• Clear visual differentiation between strengths.
• Reliable dissolution and bioavailability.

Product attribute	Gleostine profile
Active ingredient	Lomustine
Dosage form	Oral hard capsule
Strengths	10 mg, 40 mg, 100 mg
Therapeutic category	Antineoplastic alkylating agent
Primary use	Recurrent or progressive brain tumors, including glioblastoma and Hodgkin lymphoma in specified settings
Administration	Intermittent oral dosing, generally under oncology supervision
Key formulation issue	Dose accuracy and handling of a cytotoxic powder
Key commercial issue	Limited-volume specialty oncology supply

Gleostine is not a biologic. Biosimilar competition is therefore not applicable. Any follow-on competition would occur through an abbreviated new drug application, a 505(b)(2) application, or a separately approved lomustine product.

What excipient strategy is most suitable for Gleostine?

The strongest strategy is a conservative, quality-focused capsule formulation rather than a reformulation that materially changes clinical use.

Capsule-shell optimization

Gelatin is the established capsule-shell material identified in the FDA labeling. A manufacturer could evaluate hypromellose or other non-gelatin shells where there is a commercial reason, such as:

• Vegetarian or religious dietary requirements.
• Reduced dependence on animal-derived materials.
• Improved moisture performance.
• Better compatibility with automated capsule handling.
• Regional market requirements.

A shell substitution would require comparative pharmaceutical development and regulatory support. The change would not automatically create meaningful patent protection. Its value would come from supply-chain differentiation, customer requirements, or improved manufacturing performance.

Colorant substitution

Capsule colorants are potentially important because some manufacturers and hospital systems seek to reduce or eliminate certain synthetic dyes. A dye-free or alternative-color presentation could support:

• Institutional formulary preferences.
• International regulatory alignment.
• Reduced concern over colorant sensitivities.
• A simplified global capsule platform.
• Distinct product branding without changing the active ingredient.

Colorant changes must preserve capsule identification and prevent medication errors. They also require assessment of photostability, extractables, appearance, and label consistency.

Fill excipient selection

The fill blend must support low-dose uniformity, powder flow, capsule-machine performance, and dissolution. Suitable excipient classes may include:

• Microcrystalline cellulose for bulk and flow.
• Lactose or mannitol as diluents, subject to compatibility and patient-specific considerations.
• Colloidal silicon dioxide as a glidant.
• Magnesium stearate or another lubricant at a controlled concentration.
• Crospovidone or related disintegrants where needed.

The selection cannot be inferred from the public label alone. The formulation must be developed around lomustine’s stability profile, particle size, potency, segregation risk, and occupational containment requirements. At the 10 mg strength, blend uniformity is particularly important because the active represents a smaller fraction of the total fill mass.

Moisture and oxygen control

The commercial value of an excipient strategy may be greater when combined with packaging. Candidate approaches include:

• High-barrier blister packaging.
• Unit-dose bottles with desiccants.
• Low-moisture capsule shells.
• Nitrogen displacement during packaging.
• Reduced headspace oxygen.
• Light-protective packaging.

These measures can improve shelf-life robustness and reduce pharmacy handling concerns. They may also support decentralized distribution to oncology practices and specialty pharmacies.

What excipient patents could protect a Gleostine follow-on product?

A conventional capsule made with standard excipients is unlikely to support a strong standalone patent position. Patentability would be more credible where the formulation solves a documented technical problem.

Potential claim areas include:

1. A lomustine capsule with a defined moisture limit and enhanced stability.
2. A low-dose blend with specified content-uniformity performance.
3. A non-gelatin capsule that maintains dissolution and stability under accelerated conditions.
4. A colorant-free or reduced-colorant capsule with strength-specific visual identification.
5. A containment-compatible capsule and package system for cytotoxic handling.
6. A unit-dose package that limits operator exposure during dispensing.
7. A formulation with defined particle-size distribution and excipient ratios.
8. A manufacturing process that reduces segregation or powder loss.

The strongest claims would combine composition, process, and performance limitations. A broad claim covering "lomustine plus a pharmaceutically acceptable excipient" would face substantial validity and prior-art risk because lomustine capsules have been marketed for decades.

Trade secrets may have greater practical value than patents for:

• Powder-handling parameters.
• Blending order.
• Lubrication time.
• Encapsulation settings.
• Cleaning procedures.
• Containment controls.
• Stability-indicating analytical methods.
• Yield-improvement techniques.

When does Gleostine lose exclusivity?

Gleostine does not have a meaningful remaining new chemical entity exclusivity period. Lomustine was approved in the United States decades ago, and the active ingredient is an established generic molecule. The commercial product’s protection is therefore based primarily on brand position, supply continuity, regulatory execution, manufacturing know-how, and market concentration rather than current NCE exclusivity [1, 2].

Exclusivity category	Gleostine assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not a current broad barrier to lomustine competition
Pediatric exclusivity	No meaningful current barrier identified
Patent-based exclusivity	No material active-ingredient barrier expected from the vintage of the molecule
Biosimilar protection	Not applicable
Commercial protection	Brand recognition, specialty distribution, supply reliability, and limited competition

A definitive live patent conclusion requires review of the current FDA Orange Book and applicable patent databases. The commercial implication remains clear: excipient innovation would need to create a regulatory, manufacturing, or procurement advantage rather than merely extend an old compound patent.

What is the Orange Book status of Gleostine?

Gleostine is an FDA-approved oral lomustine product. The FDA Orange Book is the relevant source for determining whether the reference product has current listed patents, exclusivity codes, and therapeutic-equivalence information [2].

For a potential generic applicant, the key questions are:

• Whether the reference listing has active patents.
• Whether any listed patent covers the formulation, method of use, or packaging.
• Whether a Paragraph IV certification is required.
• Whether the reference product has a listed 30-month-stay risk.
• Whether an ANDA applicant can demonstrate pharmaceutical equivalence and bioequivalence.

Because lomustine is an older product, the principal regulatory risk is likely product development and manufacturing execution rather than a long remaining patent term. A generic applicant still must evaluate the current listing, labeling, strength portfolio, inactive ingredients, dissolution, and bioequivalence pathway.

What Paragraph IV challenges and generic entry risks exist?

A Paragraph IV challenge would be relevant only if an unexpired patent is listed for the reference product. The public commercial history of lomustine suggests that any current entry barrier is more likely to arise from formulation, method-of-use, or regulatory issues than from the underlying active ingredient.

Potential generic launch scenarios include:

Direct generic capsule

A conventional 10 mg, 40 mg, and 100 mg capsule would target the principal prescribing and dispensing requirements. The main barriers would be:

• Safe handling of a cytotoxic active.
• Low-volume commercial economics.
• Content uniformity at the 10 mg strength.
• Reliable access to qualified capsule-filling capacity.
• Bioequivalence and dissolution performance.
• Hospital and specialty-pharmacy contracting.

Selective-strength launch

A company could launch the 40 mg and 100 mg strengths first, then add the 10 mg strength. This approach could reduce initial development complexity but would limit coverage for dose adjustment and combination regimens.

505(b)(2) formulation

A 505(b)(2) product could pursue a different capsule shell, packaging system, or modified dosage form. The route would be more commercially attractive if it produced a measurable benefit, such as improved stability, reduced handling risk, or a clinically useful administration profile.

Authorized or licensed generic

A licensed generic arrangement could reduce market-entry risk by using an existing manufacturing platform or commercial partner. Its value would depend on access to reliable supply and the ability to compete against the established Gleostine brand.

What formulations are protected or commercially differentiated?

The public Gleostine formulation is a conventional oral capsule. There is no evident basis to treat it as a modified-release, liposomal, nanoparticle, or other advanced delivery product. The commercially relevant formulation distinctions are therefore likely to be:

• Capsule-shell composition.
• Colorant system.
• Fill excipient system.
• Moisture protection.
• Unit-dose packaging.
• Handling and containment configuration.
• Stability profile.

A differentiated formulation should target a customer problem. A dye-free capsule may help procurement, but it may not justify a premium. A low-moisture shell paired with unit-dose packaging could have greater value if it improves distribution and pharmacy workflow. A hazardous-drug containment system could create a stronger institutional proposition if it reduces operator exposure without increasing administration complexity.

How strong is the Gleostine patent estate?

The patent estate around the lomustine active ingredient is commercially weak because of the molecule’s age. Any value in a current estate would more likely be concentrated in narrow formulation, manufacturing, packaging, or method-of-use claims.

Patent category	Likely strength
Lomustine compound claims	Very weak or expired
Basic oral capsule claims	Weak due to extensive prior art
Standard excipient combinations	Weak unless tied to unexpected performance
Moisture-stable formulation	Moderate if supported by comparative data
Cytotoxic containment packaging	Moderate, depending on claim scope
Manufacturing process	Potentially useful as trade secret; patent value depends on novelty
Method-of-use claims	Potentially relevant but vulnerable to label and prior-art issues

A strong patent position would require comparative data showing that the formulation provides a non-obvious improvement in stability, content uniformity, dissolution, manufacturability, or handling safety.

Which companies are positioned to challenge Gleostine?

Competition can come from three groups:

1. Generic drug manufacturers with cytotoxic oral solid-dose capabilities.
2. Specialty oncology companies seeking a lower-cost lomustine product.
3. Excipient, capsule, packaging, and CDMO suppliers partnering with an ANDA or 505(b)(2) sponsor.

The most credible entrants are companies that already handle hazardous oral oncology products and can support containment, cleaning validation, occupational exposure controls, and low-volume commercial manufacturing. A conventional consumer-health capsule manufacturer would face a less favorable operating profile.

NextSource Pharma has been associated with Gleostine commercialization in the United States. The product’s market position reflects its established use and specialty distribution rather than a modern formulation platform [3].

What licensing and commercial opportunities exist?

The principal licensing opportunities are platform-based rather than molecule-based.

Excipient suppliers

Suppliers can offer:

• Low-moisture capsule shells.
• Hypromellose capsules.
• Dye-free color systems.
• Direct-compression or low-segregation excipient blends.
• Cytotoxic-compatible packaging components.
• Stability-enhancing packaging systems.

CDMOs

A CDMO could provide:

• Potent-compound handling.
• Encapsulation under containment.
• Small-batch clinical supply.
• ANDA exhibit-batch manufacturing.
• Stability programs.
• Commercial supply of selected strengths.
• Analytical method development and validation.

Specialty-pharmacy and packaging partners

Unit-dose packaging and closed-transfer systems may create value for oncology clinics, hospitals, and specialty pharmacies. The opportunity is strongest where the system reduces repackaging, minimizes tablet or capsule manipulation, and improves chain-of-custody control.

Licensing structure

A practical agreement could combine:

• Upfront technology access.
• Development milestones.
• Regulatory milestones.
• Per-unit royalties.
• Minimum annual volumes.
• Geographic rights.
• Exclusivity limited to a defined shell, packaging, or formulation technology.

A broad exclusive license for standard excipients would be difficult to justify. A narrower license tied to documented stability or containment performance would be more defensible.

What FDA regulatory issues affect a Gleostine excipient strategy?

The FDA would evaluate inactive-ingredient changes through the applicable abbreviated or full application pathway. Key requirements include:

• Pharmaceutical equivalence.
• Comparable dissolution.
• Bioequivalence where required.
• Stability data.
• Capsule-shell characterization.
• Impurity and degradation-product assessment.
• Compatibility of the fill blend with the shell.
• Labeling updates.
• Manufacturing controls for a hazardous drug.

FDA guidance on inactive ingredients and ANDA development is relevant to excipient selection and regulatory justification [4]. The applicant must also consider whether a proposed excipient or concentration is supported by the FDA Inactive Ingredient Database for the relevant route and dosage form [5].

The handling profile is a separate operational issue. Lomustine is a cytotoxic antineoplastic drug, so manufacturing and dispensing controls should address worker exposure, cleaning validation, waste management, and accidental capsule damage.

How does Gleostine compare with other oral oncology opportunities?

Gleostine has a smaller volume opportunity than newer oral targeted therapies, but it may offer less direct formulation complexity.

Opportunity	Formulation complexity	Patent potential	Market size	Supply-chain barrier
Gleostine follow-on capsule	Low to moderate	Low to moderate	Niche	High
Modified-release oncology product	Moderate to high	Moderate to high	Variable	Moderate
Oral targeted therapy	Moderate	High	Often larger	Moderate
Cytotoxic hospital generic	Moderate	Low	Variable	High
Specialty packaging platform	Moderate	Moderate	Cross-product	Moderate

Gleostine is attractive for a focused specialty-generic strategy, not for a broad-volume excipient play. The best opportunity is a combined product-and-service package: compliant capsule manufacture, reliable supply, and safer unit-dose handling.

What revenue exposure and launch economics matter?

Public revenue estimates for Gleostine should be treated carefully because reported figures may reflect U.S. sales, licensing arrangements, gross product revenue, or net revenue after discounts. The product’s economics are shaped by:

• Small patient population.
• High clinical value in selected oncology settings.
• Limited treatment frequency.
• Specialty-distribution concentration.
• Cytotoxic manufacturing costs.
• Need for multiple strengths.
• Inventory and expiry risk.
• Potential price pressure from generic entry.

A follow-on manufacturer could achieve commercial viability without large unit volume if it secures hospital contracts, maintains all three strengths, and avoids supply interruptions. A single-strength entrant would face greater substitution and formulary limitations.

Key Takeaways

• Gleostine is a conventional lomustine oral capsule, not an advanced drug-delivery product.
• Its relevant excipients include gelatin, titanium dioxide, and capsule colorants identified in FDA labeling.
• The best formulation opportunities are low-moisture shells, dye-free presentations, blend-uniformity improvements, and high-barrier unit-dose packaging.
• Lomustine’s compound exclusivity is long expired; commercial protection rests on brand position, supply reliability, and specialty distribution.
• Biosimilar competition does not apply because Gleostine is a small-molecule drug.
• A generic or 505(b)(2) entrant would likely face manufacturing, bioequivalence, hazardous-drug handling, and commercial-scale barriers.
• Standard excipient combinations have limited patent value. Data-supported stability, containment, or manufacturing claims have greater potential.
• The strongest commercial model combines an excipient or packaging technology with a qualified cytotoxic CDMO and specialty-market access.

FAQs

Can Gleostine be reformulated as a liquid?

A liquid lomustine product would require proof of chemical stability, dose uniformity, palatability, container compatibility, and safe handling. It could improve administration for selected patients but would introduce substantial stability and cytotoxic-exposure issues.

Is a gelatin-free Gleostine capsule commercially viable?

A gelatin-free capsule using hypromellose or another shell material is technically plausible. Its commercial value would depend on demonstrated stability, dissolution, capsule-machine performance, and customer demand.

Can a generic Gleostine product use different capsule colors?

Different colors may be possible if the product remains pharmaceutically equivalent, supports accurate strength identification, and satisfies FDA labeling and medication-error controls. Color changes would require regulatory justification.

Would a Gleostine packaging patent block generic entry?

A valid, unexpired packaging patent could restrict a particular packaging configuration. It would not necessarily prevent a generic manufacturer from using a non-infringing bottle, blister, or unit-dose system.

Is lomustine a good candidate for a specialty-generic launch?

It can be attractive for a manufacturer with cytotoxic containment capabilities, oncology distribution, and low-volume commercial infrastructure. It is less attractive for a high-volume generic strategy based solely on standard capsule manufacture.

References

1. U.S. Food and Drug Administration. (2024). Gleostine (lomustine) capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. NextSource Pharma. (2024). Gleostine product and corporate information.
4. U.S. Food and Drug Administration. (2014). Inactive ingredient database and guidance for industry: ANDAs for certain highly purified synthetic peptides.
5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.